ViGeneron GmbH of Munich closed a Series A round led by two China investors, WuXi AppTec and Sequoia Capital China. The company will use the proceeds to advance its proprietary viral vector-based gene therapy platforms and develop its two lead ophthalmic gene therapy candidates. ViGeneron's pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms: vgAAV gene therapy vectors, which allow superior transduction efficiency and intravitreal, less invasive treatment administration; and REVeRT vectors, which target diseases caused by mutations in large genes. More details.... Share this with colleagues: // //